Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest JOURNEY II Unicompartmental Knee (UK) System during the European Society of Sports Traumatology, Knee Surgery & Arthroscopy 2022 Congress being held in Paris, France.
Designed using cutting edge computer simulation to maintain normal motion and function, JOURNEY II UK is built on the heritage of one of the most clinically successful partial knees,1,2* and is the next generation of advanced design for Smith+Nephew’s partial knee portfolio. With customized sizing options, through the introduction of a lateral-specific tibia baseplate and a large size range for femoral components and tibia baseplates, the JOURNEY II UK is designed to provide the most tailored fit of any partial knee on the market.
JOURNEY II UK provides a highly personalized approach to partial knee arthroplasty, via a modular, two-tray configuration and instrumentation that can be customized to match a familiar surgical flow, which may drive value and cost reduction in sterilization costs through a reduced OR footprint.3
“The ground-breaking introduction of a lateral-specific baseplate design in conjunction with a ten size range for femoral and tibial components makes JOURNEY II UK unique in its capacity to offer an individualized fit and balance for each patient anatomy” said Dr. Federico d’Amario, Humanitas Hospital, San Pio X, Milan, Italy.
Paired with proprietary OXINIUM◊ Technology, JOURNEY II UK can also be used with Smith+Nephew’s innovative, robotics-assisted CORI◊ Surgical System, further reducing its two-tray footprint4,5 and offering increased value6† to healthcare providers in a comprehensive solution to unicompartmental knee procedures.
“Smith+Nephew has a successful legacy in the development of unicompartmental knee solutions and our JOURNEY II UK System is the next innovative chapter in that story. We are pleased to announce the completion of the first 500 implants in Europe under a limited market release and are excited to start the full commercial launch in 2022,” said Peter Coenen, President EMEA at Smith+Nephew.
Invitation to Smith+Nephew ESSKA Lunch Symposium on 29 April
JOURNEY II UK will be showcased as part of the Smith+Nephew Lunch Symposium “Overcoming UKA challenges with a new Implant Design and Handheld Robotics” at the ESSKA 2022 Congress on 29 April at 12:30pm CEST.
Enquiries
| Media |
|
| David Snyder | +1 978-749-1440 |
| Smith+Nephew |
|
|
|
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
References
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2021 Annual Report. Adelaide: AOA, 2021.
- National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. 18th Annual Report. 2021. Hertfordshire, UK.
- Capra R, Bini SA, Bowden DE, et al. Implementing a perioperative efficiency initiative for orthopedic surgery instrumentation at an academic center: A comparative before-and-after study. Medicine (Baltimore). 2019;98(7):e14338.
- Smith+Nephew 2019. Instrument Tray Design Verification. Internal Report. TR1496.
- Smith+Nephew 2019. Optimus Tray Design Description. Internal Report. DD0066.
- Nherera L, Verma S, Trueman P. Cost-effectiveness of robotic-assisted unicompartmental knee arthroplasty (r-UKA) using NAVIOTM compared to traditional unicompartmental knee arthroplasty (t-UKA) for patients with unicompartmental osteoarthritis. Poster presented at: ISPOR 18-22 May, 2019; New Orleans, Los Angeles, USA.
* We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. {Additional Contributors to be added where necessary}. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.
† Based on a Markov model of 100 patients, revision rates based on: a retrospective, multi-center study, n=128 for NAVIO™ Surgical System; UK NJR data for non-robotics assisted procedures.
Note: Evidence referenced in this release used ZUK data and is not specific to JOURNEY II UK.